Biosimilars Reach 17% in Valencia, Spain

Biosimilars penetration into Valencia’s market in 2015 reached a figure of 17.61% of total drugs expenditure in hospitals. However, the distribution of biosimilar usage varied significantly depending on the drug in question, ranging from 3% (follitropin alpha) to 55% (filgrastim).

Read the full story here.

Tagged with

Published 12. October 2016 in News Spain